KKR to invest in Nordic Bioscience for £72m.

KKR is set to invest in Nordic Bioscience, a Danish company engaged in biomarker development, for £72m. “I am excited to welcome KKR as a valued investor to the Nordic Bioscience team and to have their support in building on our strategy of bringing innovative novel diagnostic biomarkers and drug candidates to the market for the benefit of patients. Our fast-moving customers have high expectations, and KKR’s investment will propel Nordic Bioscience forward so that we can continue to meet these expectations. At the core of Nordic Bioscience is collaboration, among our team, with our partners and customers and now with KKR,” Morten Karsdal, Nordic Bioscience CEO.